Background: The relationship between cancer and dementia is triggering growing research interest. Several preclinical studies have provided the biological rationale for the repurposing of specific anticancer agents in Alzheimer’s disease (AD), and a growing number of research protocols are testing their efficacy and safety/ tolerability in patients with AD. Methods: The aim of the present systematic review was to provide an overview on the repurposing of approved anticancer drugs in clinical trials for AD by considering both ongoing and completed research protocols in all phases. In parallel, a systematic literature review was conducted on PubMed, ISI Web, and the Cochrane Library to identify published clinical studies on repurposed anticancer agents in AD. Results: Based on a structured search on the ClinicalTrials.gov and the EudraCT databases, we identified 13 clinical trials testing 11 different approved anticancer agents (five tyrosine kinase inhibitors, two retinoid X receptor agonists, two immunomodulatory agents, one histone deacetylase inhibitor, and one monoclonal antibody) in the AD continuum. The systematic literature search led to the identification of five published studies (one phase I, three phase II, and one phase IIb/III) reporting the effects of antitumoral treatments in patients with mild cognitive impairment or AD dementia. The clinical findings and the methodological characteristics of these studies are described and discussed. Conclusion: Anticancer agents are triggering growing interest in the context of repurposed therapies in AD. Several clinical trials are underway, and data are expected to be available in the near future. To date, data emerging from published clinical studies are controversial. The promising results emerging from preclinical studies and identified research protocols should be confirmed and extended by larger, adequately designed, and high-quality clinical trials.

Anticancer drugs repurposed for Alzheimer’s disease: a systematic review / Ancidoni, Antonio; Bacigalupo, Ilaria; Remoli, Giulia; Lacorte, Eleonora; Piscopo, Paola; Sarti, Giulia; Corbo, Massimo; Vanacore, Nicola; Canevelli, Marco. - In: ALZHEIMER'S RESEARCH & THERAPY. - ISSN 1758-9193. - 13:1(2021). [10.1186/s13195-021-00831-6]

Anticancer drugs repurposed for Alzheimer’s disease: a systematic review

Ancidoni, Antonio
Primo
;
Remoli, Giulia;Sarti, Giulia;Vanacore, Nicola
Penultimo
;
Canevelli, Marco
Ultimo
2021

Abstract

Background: The relationship between cancer and dementia is triggering growing research interest. Several preclinical studies have provided the biological rationale for the repurposing of specific anticancer agents in Alzheimer’s disease (AD), and a growing number of research protocols are testing their efficacy and safety/ tolerability in patients with AD. Methods: The aim of the present systematic review was to provide an overview on the repurposing of approved anticancer drugs in clinical trials for AD by considering both ongoing and completed research protocols in all phases. In parallel, a systematic literature review was conducted on PubMed, ISI Web, and the Cochrane Library to identify published clinical studies on repurposed anticancer agents in AD. Results: Based on a structured search on the ClinicalTrials.gov and the EudraCT databases, we identified 13 clinical trials testing 11 different approved anticancer agents (five tyrosine kinase inhibitors, two retinoid X receptor agonists, two immunomodulatory agents, one histone deacetylase inhibitor, and one monoclonal antibody) in the AD continuum. The systematic literature search led to the identification of five published studies (one phase I, three phase II, and one phase IIb/III) reporting the effects of antitumoral treatments in patients with mild cognitive impairment or AD dementia. The clinical findings and the methodological characteristics of these studies are described and discussed. Conclusion: Anticancer agents are triggering growing interest in the context of repurposed therapies in AD. Several clinical trials are underway, and data are expected to be available in the near future. To date, data emerging from published clinical studies are controversial. The promising results emerging from preclinical studies and identified research protocols should be confirmed and extended by larger, adequately designed, and high-quality clinical trials.
2021
Alzheimer’s disease, Cancer, Anticancer drugs, Clinical trials, Drug repositioning
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Anticancer drugs repurposed for Alzheimer’s disease: a systematic review / Ancidoni, Antonio; Bacigalupo, Ilaria; Remoli, Giulia; Lacorte, Eleonora; Piscopo, Paola; Sarti, Giulia; Corbo, Massimo; Vanacore, Nicola; Canevelli, Marco. - In: ALZHEIMER'S RESEARCH & THERAPY. - ISSN 1758-9193. - 13:1(2021). [10.1186/s13195-021-00831-6]
File allegati a questo prodotto
File Dimensione Formato  
Ancidoni_Anticancer drugs repurposed_2021.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.22 MB
Formato Adobe PDF
1.22 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1546053
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 15
social impact